Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
UBS
Merck
Julphar
Farmers Insurance
McKesson
Accenture
Fuji
Express Scripts

Generated: June 21, 2018

DrugPatentWatch Database Preview

OXTRIPHYLLINE - Generic Drug Details

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

What are the generic drug sources for oxtriphylline and what is the scope of oxtriphylline freedom to operate?

Oxtriphylline
is the generic ingredient in four branded drugs marketed by Parke Davis, Morton Grove, Watson Labs, and Warner Chilcott Llc, and is included in seven NDAs. Additional information is available in the individual branded drug profile pages.

There are three drug master file entries for oxtriphylline.
Summary for OXTRIPHYLLINE
US Patents:0
Tradenames:4
Applicants:4
NDAs:7
Drug Master File Entries: 3
Bulk Api Vendors: 17
Patent Applications: 2,349
DailyMed Link:OXTRIPHYLLINE at DailyMed
Synonyms for OXTRIPHYLLINE
1,3-dimethyl-2-oxopurin-6-olate; 2-hydroxyethyl(trimethyl)azanium
1,3-dimethyl-2,6-dioxo-7H-purin-7-ide; choline
13930-27-3
146-71-4
3K045XR58X
4499-40-5
56553-57-2
AC1LCVCP
AKOS025392171
API0015829
CCG-213695
CHEMBL1200434
Choline theophyllinate
Choline theophyllinate (INN)
Choline theophyllinate [INN]
Choline theophylline
Choline theophylline (JAN)
CHOLINETHIEOPHYLLINATE
cholintheophyllinat
D02017
DB01303
HMS2094A07
KS-1426
MolPort-035-783-495
NSC-760431
NSC760431
Oxtriphylline (USP)
Oxtriphylline [USP]
Oxytrimethylline
Pharmakon1600-01505759
SCHEMBL152854
SCHEMBL4629
Theocolin
Theocolin (TN)
Theophyline - choline mixt
UNII-3K045XR58X

US Patents and Regulatory Information for OXTRIPHYLLINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Parke Davis CHOLEDYL oxtriphylline TABLET, DELAYED RELEASE;ORAL 009268-007 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Watson Labs OXTRIPHYLLINE oxtriphylline TABLET, DELAYED RELEASE;ORAL 087866-001 Aug 25, 1983 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Warner Chilcott Llc CHOLEDYL SA oxtriphylline TABLET, EXTENDED RELEASE;ORAL 087863-001 May 24, 1983 RX No Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Watson Labs OXTRIPHYLLINE oxtriphylline TABLET, DELAYED RELEASE;ORAL 087835-001 Aug 25, 1983 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
AstraZeneca
Fuji
UBS
Argus Health
Boehringer Ingelheim
Healthtrust
Fish and Richardson
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.